CLL and follicular lymphoma, which benefit from the use of obinutuzumab, are both characterized by high-level BCL2 expression (Goede et al., 2014, 2015; Marcus et al., 2017), whereas DLBCL is a more heterogeneous entity (Schmitz et al., 2018). Here, BCL2 is linked to diffuse large B-cell lymphoma.